There is growing recognition that the pathophysiological process of Alzheimer disease (AD)
begins many years prior to clinically obvious symptoms, and the concept of a …

The central nervous system has been considered off-limits to antibody therapeutics.
However, recent advances in preclinical and clinical drug development suggest that …

Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features seen
on neuroimaging include recent small subcortical infarcts, lacunes, white matter …

Inflammatory processes are important in the pathogenesis of Alzheimer's disease and in
response to amyloid-β immunotherapy. We investigated the expression of multiple …

Objective Cerebral amyloid angiopathy–related inflammation (CAA‐ri) is characterized by
vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects …

Vascular pathology is a major feature of Alzheimer's disease (AD) and other dementias. We
recently showed that chronic administration of the target-of-rapamycin (TOR) inhibitor …

Background Three small trials suggest that intravenous immunoglobulin can affect
biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety …

Importance β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ
deposition accelerates gray matter atrophy at early stages of the disease even before …

Objective: To investigate whether cortical superficial siderosis (cSS) on MRI, especially if
disseminated (involving more than 3 sulci), increases the risk of future symptomatic lobar …

Regenerative therapeutics hold the promise of self-renewal and repair. Ageing and age-
associated neurodegenerative diseases are marked by a decline in self-renewal and repair …